KMT2D and neoplasm: In B-lymphoma cells and in tumor samples of DLBCL patients, we showed that KMT2D mutations decreased H3K4me3, downregulated tumor suppressor gene FBXW727, and more importantly, activated downstream NOTCH/MYC signaling, which are critically involved in DLBCL 28.